RecruitingNot ApplicableNCT04525989
Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT)
Preoperative Short-Course Radiation Therapy With PROtons Compared to Photons In High-Risk RECTal Cancer (PRORECT): A Prospective Randomized Swedish Phase II Trial
Sponsor
Alexander Valdman
Enrollment
254 participants
Start Date
Apr 20, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
To investigate a potential toxicity benefit of preoperative radiation therapy with protons compared to conventional photon beam radiation therapy in patients with locally advanced rectal cancer.
Eligibility
Min Age: 18 Years
Inclusion Criteria19
- Biopsy-proven, newly diagnosed primary rectal adenocarcinoma, i.e. with the lowest part of the tumour less than 16 cm from the anal verge detected using a rigid rectoscope.
- Locally advanced tumour fulfilling at least one of the following criteria on pelvic MRI indicating high risk of failing locally and/or systemically:
- Clinical stage (c) T4b, i.e. infiltration of an adjacent organ or structure like the prostate, urinary bladder, uterus, sacrum, pelvic floor or side-wall (according to TNM version 8).
- cT4a, i.e. peritoneal involvement.
- Extramural vascular invasion (EMVI+).
- N2-status regarded as metastatic according to ESGAR consensus criteria
- Positive MRF, i.e. tumor or lymph node one mm or less from the mesorectal fascia.
- Metastatic lateral nodes (lat LN+) according to ESGAR consensus criteria
- Staging done within 6 weeks before start of radiotherapy. No contraindications to chemotherapy with CAPOX including adequate blood counts, (within 5 weeks prior to randomisation):
- white blood count ≥4.0 x 10\*9/L
- platelet count ≥100 x 10\*9/L
- clinically acceptable haemoglobin levels
- creatinine levels indicating renal clearance of ≥50 ml/min
- bilirubin ˂35 µmol/l.
- ECOG performance score ≤1
- Patient is considered to be mentally and physically fit for chemotherapy with CAPOX as judged by the oncologist.
- Age ≥18 years
- Written informed consent.
- Adequate potential for follow-up.
Exclusion Criteria14
- Extensive growth into cranial part of the sacrum (above S3) or the lumbosacral nerve roots indicating that surgery will never be possible even if substantial tumour down-sizing is seen.
- Presence of metastatic disease or recurrent rectal tumour. Familial Adenomatosis Polyposis coli (FAP), Hereditary Non-Polyposis Colorectal Cancer (HNPCC), active Crohn's disease or active ulcerative Colitis.
- Concomitant malignancies, except for adequately treated basocellular carcinoma of the skin or in situ carcinoma of the cervix uteri. Subjects with prior malignancies must be disease-free for at least 5 years.
- Known DPD deficiency.
- Any contraindications to MRI (e.g. patients with pacemakers).
- Medical or psychiatric conditions that compromise the patient's ability to give informed consent.
- Concurrent uncontrolled medical conditions.
- Any investigational treatment for rectal cancer within the past month.
- Pregnancy or breast feeding.
- Patients with known malabsorption syndromes or a lack of physical integrity of the upper gastrointestinal tract.
- Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac dysrhythmia, e.g. atrial fibrillation, even if controlled with medication) or myocardial infarction within the past 12 months.
- Patients with symptoms of peripheral neuropathy.
- Patients with pacemaker or ICD
- Patients with bilateral hip protheses
Interventions
RADIATIONRadiation therapy
5 x 5 Gy external radiation therapy
Locations(9)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04525989
Related Trials
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT046742671 location
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT058069319 locations
A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer
NCT066374626 locations
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
NCT0701157614 locations
SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak
NCT072097871 location